Metagenomi Therapeutics

MGXNasdaq United States Health Care Biotechnology: Biological Products (No Diagnostic Substances)

Market cap

$27.721 M

$0.73 -7.11%

Close of 6 Nov 2026

As of 6 Nov 2026, Metagenomi Therapeutics (MGX) has a market capitalization of $27.7M. Market cap measures the value of outstanding equity at market prices; company totals combine applicable share classes. Prices and market caps come from Nasdaq, with financial fundamentals from SEC filings. See sources and calculation details.

Revenue

$25.2M

#2907 by revenue

Earnings

-$87.9M

Loss-making

Shares outstanding

37,777,105

Latest filing cover page

P/E ratio

—

Cap ÷ net income

Biotechnology: Biological Products (No Diagnostic Substances), ranked by market cap

All 163 →

#133ElutiaELUT$34.7M
#134Aligos TherapeuticsALGS$28.6M
#135Metagenomi TherapeuticsMGX$27.7M
#136Evaxion A/SEVAX$25.5M
#137Cel SciCVM$24.6M

What if Metagenomi Therapeutics were worth as much as…

Open the what-if tool →

Gold $28.2T

$747,459.96

Per share 1,018,615× higher

Bitcoin $1.53T

$40,443.76

Per share 55,116× higher

Apple $5.02T

$132,773.08

Per share 180,939× higher

Or at a round number

$50.0M $100.0M $200.0M $500.0M

Where these numbers come from

Share counts and financials for Metagenomi Therapeutics are taken from its own SEC filings via EDGAR: public record, not an estimate. Market cap is shares outstanding multiplied by the latest close. Read the methodology.